An Insider at Hims & Hers Disposed of Over $3 Million in Stock. Here's What Long-Term Investors Should Know

Jonathan Ponciano, The Motley Fool

Wed, August 19, 2026 at 12:17 PM GMT+3 5 min read

HIMS +4.28%

Chief Financial Officer Oluyemi Okupe reported the disposal of 101,000 shares of Hims & Hers Health, Inc. (NYSE:HIMS) across transactions occurring between June 18 and August 14, according to a recent SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average sale price ($31.92); post-transaction value based on the August 17 market close ($28.61).

Key questions

How did the mechanical structure of these trades impact the net change in ownership?
The transaction was primarily driven by the exercise of 101,208 stock options at a strike price of $5.01 per share. While 64,771 shares were sold on the open market, an additional 36,437 shares were withheld by the company to cover the tax liabilities associated with the vesting of restricted stock units.
What is the executive's remaining equity exposure following this disposition?
Okupe retains a direct equity position of 264,117 shares of Class A Common Stock. In addition to these common shares, the executive holds additional derivative securities, which maintain their alignment with long-term shareholder value.
Does this transaction reflect a change in the executive's outlook on the firm?
The sales were executed pursuant to a Rule 10b5-1 trading plan established on May 21, 2025. This arrangement allows for automated selling at pre-arranged intervals, which helps decouple transaction timing from recent share price volatility or specific corporate developments.

Company Overview

Company Snapshot

Hims & Hers operates a comprehensive digital health platform that delivers prescription medications, over-the-counter drugs, medical devices, cosmetics, and dietary supplements directly to consumers through its websites and mobile application.
The company generates revenue through a direct-to-consumer telemedicine model, connecting patients with licensed medical professionals for virtual consultations and facilitating the sale of health and wellness products.
The company primarily serves consumers seeking convenient access to healthcare services and products, targeting individuals who prefer digital-first health solutions and direct-to-consumer pharmaceutical and wellness offerings.

Hims & Hers Health is a leading digital health platform with a market capitalization of $6.4 billion and TTM revenue of $2.6 billion, positioning it as a significant player in the telehealth and direct-to-consumer healthcare space. The company's integrated platform model--combining virtual medical consultations with direct product fulfillment--creates operational leverage and customer stickiness across its growing user base. Despite current net losses, the company's substantial revenue scale and expanding digital health market opportunity underscore its strategic positioning within the evolving healthcare delivery landscape.

What this transaction means for investors

Okupe has been running this same trading plan since May of last year, and this two-month stretch from mid-June to mid-August is just the latest installment, with an option exercise at a $5.01 strike, some shares sold on the plan's schedule, and some withheld for taxes. He's filed close to a dozen of these this year alone, at prices ranging from the low $20s to the mid $30s, depending on when the window fell, and ultimately, a CFO selling on autopilot through a stock's ups and downs is essentially just noise relative to company performance.

What matters more is what Okupe's actual job produced this quarter. On the latest earnings call, he told investors gross margin compression from the shift toward branded weight loss and international revenue "will remain below the levels we have historically achieved," and second-quarter numbers backed that up, showing margins fell to 64% from 76% a year earlier. For long-term investors, that's what really matters going forward, especially as the company doubles down on this strategic pivot.

Should you buy stock in Hims & Hers Health right now?

Before you buy stock in Hims & Hers Health, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $409,970!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,381,040!*

That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of August 19, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy.

An Insider at Hims & Hers Disposed of Over $3 Million in Stock. Here's What Long-Term Investors Should Know was originally published by The Motley Fool